Log in

NASDAQ:EXEL - Exelixis Stock Price, Forecast & News

$17.65
+0.04 (+0.23 %)
(As of 12/13/2019 03:53 AM ET)
Today's Range
$17.47
Now: $17.65
$17.78
50-Day Range
$15.21
MA: $16.59
$17.76
52-Week Range
$15.02
Now: $17.65
$25.31
Volume2.58 million shs
Average Volume3.07 million shs
Market Capitalization$5.36 billion
P/E Ratio12.34
Dividend YieldN/A
Beta1.78
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXEL
CUSIP30161Q10
Phone650-837-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$853.83 million
Cash Flow$1.59 per share
Book Value$4.31 per share

Profitability

Net Income$690.07 million

Miscellaneous

Employees484
Market Cap$5.36 billion
Next Earnings Date2/11/2020 (Estimated)
OptionableOptionable

Receive EXEL News and Ratings via Email

Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.


Exelixis (NASDAQ:EXEL) Frequently Asked Questions

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) posted its quarterly earnings data on Wednesday, October, 30th. The biotechnology company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of $0.19 by $0.12. The biotechnology company earned $271.70 million during the quarter, compared to analyst estimates of $228.17 million. Exelixis had a net margin of 64.05% and a return on equity of 25.55%. The business's quarterly revenue was up 20.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.44 earnings per share. View Exelixis' Earnings History.

When is Exelixis' next earnings date?

Exelixis is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Exelixis.

What price target have analysts set for EXEL?

8 equities research analysts have issued 1-year price objectives for Exelixis' stock. Their forecasts range from $19.00 to $35.00. On average, they expect Exelixis' stock price to reach $25.88 in the next year. This suggests a possible upside of 46.6% from the stock's current price. View Analyst Price Targets for Exelixis.

What is the consensus analysts' recommendation for Exelixis?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exelixis.

Has Exelixis been receiving favorable news coverage?

Headlines about EXEL stock have trended neutral recently, according to InfoTrie. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Exelixis earned a daily sentiment score of 0.4 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Exelixis.

Are investors shorting Exelixis?

Exelixis saw a decline in short interest during the month of November. As of November 15th, there was short interest totalling 15,690,000 shares, a decline of 5.0% from the October 31st total of 16,520,000 shares. Based on an average trading volume of 2,790,000 shares, the short-interest ratio is currently 5.6 days. Currently, 5.3% of the company's shares are sold short. View Exelixis' Current Options Chain.

Who are some of Exelixis' key competitors?

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Incyte (INCY), Intel (INTC), Celgene (CELG) and Corbus Pharmaceuticals (CRBP).

Who are Exelixis' key executives?

Exelixis' management team includes the folowing people:
  • Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 71)
  • Dr. Michael M. Morrissey, CEO, Pres & Director (Age 58)
  • Mr. Christopher J. Senner, Exec. VP & CFO (Age 51)
  • Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 58)
  • Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 50)

Who are Exelixis' major shareholders?

Exelixis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (3.44%), First Trust Advisors LP (1.32%), Pictet Asset Management Ltd. (1.00%), Stephens Investment Management Group LLC (0.29%), Chicago Capital LLC (0.26%) and Rhumbline Advisers (0.25%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

Which major investors are selling Exelixis stock?

EXEL stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Millennium Management LLC, Rhenman & Partners Asset Management AB, SG Americas Securities LLC, Great West Life Assurance Co. Can, Capital Management Corp VA, Stifel Financial Corp and Tower Research Capital LLC TRC. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

Which major investors are buying Exelixis stock?

EXEL stock was bought by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Great Point Partners LLC, State Street Corp, Man Group plc, State of New Jersey Common Pension Fund D, Mackay Shields LLC, California Public Employees Retirement System and Squarepoint Ops LLC. View Insider Buying and Selling for Exelixis.

How do I buy shares of Exelixis?

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $17.65.

How big of a company is Exelixis?

Exelixis has a market capitalization of $5.36 billion and generates $853.83 million in revenue each year. The biotechnology company earns $690.07 million in net income (profit) each year or $1.43 on an earnings per share basis. Exelixis employs 484 workers across the globe.View Additional Information About Exelixis.

What is Exelixis' official website?

The official website for Exelixis is http://www.exelixis.com/.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]


MarketBeat Community Rating for Exelixis (NASDAQ EXEL)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  437 (Vote Outperform)
Underperform Votes:  396 (Vote Underperform)
Total Votes:  833
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe EXEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel